The global immune checkpoint inhibitors industry generated $34.9B in 2021, and is anticipated to generate $155.1B by 2031, witnessing a CAGR of 16.1% from 2022 to 2031, according to a report from Allied Market Research.
Rise in incidence of cancer across the world, surge in global geriatric population, and supportive reimbursement policies for immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. On the other hand, high cost of immune checkpoint inhibitors impedes the growth to some extent. However, an increase in the number of pipeline drugs is expected to create lucrative opportunities in the industry.